Correlation between bradykinin concentration and blood pressure during Rheocarna therapy: A single-center case series.
Ther Apher Dial
; 28(3): 453-459, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38173128
ABSTRACT
INTRODUCTION:
A novel LDL (low-density lipoprotein) apheresis therapeutic option, Rheocarna, has garnered attention as an alternative therapy for chronic limb-threating ischemia (CLTI). Bradykinin-mediated vasodilation is involved in the effects of LDL apheresis and a decrease in blood pressure (BP), but the changes in bradykinin concentration during Rheocarna therapy are unknown.METHODS:
The study involved patients with CLTI treated with Rheocarna at our hospital, from April 2022 to August 2023.RESULTS:
After Rheocarna therapy, skin ulcers improved in 80% of the patients. Circuit coagulation was observed in two patients with high fibrinogen levels. A decrease in BP was observed at approximately the same time when the bradykinin concentration peaked. The peak bradykinin concentration in a patient undergoing hemodialysis at the same time was considerably lower than that in the other patients.CONCLUSION:
This is the first report on the changes in bradykinin concentration under Rheocarna therapy.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Presión Sanguínea
/
Bradiquinina
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2024
Tipo del documento:
Article